Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Aditxt, Inc.

< Previous 1 2 3 Next >
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF TSX:APLI
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
From Aditxt, Inc.
Via GlobeNewswire
Tickers ADTX
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Issues Shareholder Update
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.